文献速递消化道肿瘤放疗姑息放疗与转移瘤

局部晚期直肠癌盆腔侧壁淋巴结放疗剂量提升

Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer.
PubMed 文献 · Adv Radiat Oncol · 2019-04-01

该单中心回顾性研究纳入261例直肠腺癌患者中的12例,评估新辅助放化疗期间对临床受累但未计划切除的盆腔侧壁淋巴结给予>50.4 Gy的放疗推量。推量剂量53.48-60.2 Gy,急性毒性及围手术期并发症风险低,12个月局部控制率90%。

要点

  • 对未切除的临床受累盆腔侧壁淋巴结行放疗推量耐受性良好
  • 推量剂量范围53.48-60.2 Gy,分27-30次,每次1.8-2.15 Gy
  • 12个月局部控制率为90%,中位随访18个月

核心结论

  • 新辅助放化疗期间对未切除的盆腔侧壁淋巴结行放疗剂量提升耐受性良好,急性毒性和围手术期并发症风险低,12个月局部控制率高。

研究设计与样本

  • 单中心回顾性研究,2006-2018年共261例直肠腺癌患者,其中12例接受新辅助放化疗期间对可疑盆腔侧壁淋巴结累计剂量>50.4 Gy。

主要发现

  • 12例患者中位年龄47.5岁,83%为男性,全部为T3/4期,17%为N1b期,其余为N2期,33%为M1期(均≤2个转移灶)。
  • 75%患者为中或低分化组织学,肿瘤距肛缘平均4.85 cm(范围2-8.9 cm),58%有≥2个盆腔侧壁淋巴结,平均短径1.11 cm(范围0.4-3.2 cm)。
  • 推量剂量53.48 Gy至60.2 Gy,分27至30次(每次1.8-2.15 Gy),中位随访18个月。
  • 1例接受卡培他滨联合伊立替康同步治疗的患者在新辅助放化疗期间出现3级会阴皮炎和贫血。
  • 全直肠系膜切除术中位住院时间6.5天,术后90天内1例因会阴伤口裂开需手术探查,另1例因贫血需输血;末次随访时75%患者存活,12个月局部控制率90%。

临床怎么用

  • 对于临床受累但未计划切除的盆腔侧壁淋巴结,可考虑在新辅助放化疗期间行放疗剂量提升,但需进一步研究验证。

局限性

  • 单中心回顾性研究,样本量仅12例,中位随访时间18个月较短,结论需更大样本和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lateral pelvic sidewall lymph nodes (PSW LN) may be involved in up to 24% of locoregionally advanced rectal cancers. PSW LN are not resected in total mesorectal excision (TME), and no standard of care regarding the management of PSW LN exists in the United States. We assessed our institutional experience of preoperative radiation therapy (RT) boost to clinically involved PSW LN that were not planned for resection. METHODS AND MATERIALS: Data from all patients with rectal adenocarcinoma treated between 2006 and 2018 were reviewed to identify those who received a cumulative dose of >50.4 Gy to suspicious PSW LN during neoadjuvant chemoradiation therapy (nCRT). Demographic, cancer characteristic, treatment, and toxicity data were derived from the chart. RESULTS: Of a total of 261 patients, 12 patients met the inclusion criteria. The median age was 47.5 years, and 83% of patients were men. All patients had T3/4 disease, 17% of patients had N1b disease and the remainder had N2 disease, and 33% had M1 disease (all ≤2 metastases). Seventy-five percent of patients had moderately or poorly differentiated histology. The mean distance from the anal verge was 4.85 cm (range, 2-8.9 cm), and 58% had ≥2 PSW LN with an average short axis diameter of 1.11 cm (range, 0.4-3.2 cm). Boost doses ranged from 53.48 Gy to 60.2 Gy in 27 to 30 fractions (1.8-2.15 Gy/fraction). The median follow-up time was 18 months. One patient who received concurrent capecitabine and irinotecan had grade 3 perineal dermatitis and anemia during nCRT. The median hospitalization time for TME was 6.5 days. Within 90 days of TME, 1 patient required surgical exploration for perineal wound breakdown, and another required a blood transfusion for anemia. At the time of the last follow up, 75% of patients were alive. Local control at 12 months was 90%. CONCLUSIONS: RT dose escalation to nonresected PSW LN during nCRT was well tolerated with a low risk of acute toxicity and perioperative complications and has a high rate of local control at 12 months. RT boost warrants further study in patients with clinically involved nonresected PSW LN.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hartvigson PE, Apisarnthanarax S, Schaub S, et al. Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer. Adv Radiat Oncol. 2019. PMID: 31360803. doi:10.1016/j.adro.2019.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。